ubiquinol-cytochrome c reductase hinge proteinGenealiases: MC3DN11 · QCR6 · UQCR8
Q-omics provides the consensus-scored UQCRH profile across patient tissues and cancer cell-line models. UQCRH expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UQCRH is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, UQCRH RNA expression shows 18,209 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where UQCRH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCRH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCRH survival associations across molecular data types. UQCRH RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCRH RNA expression–survival associations across cancer types. High UQCRH expression shows unfavorable associations in ACC, KICH, LIHC, SARC, SCLC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UQCRH RNA expression.
This table summarizes UQCRH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UQCRH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCRH shows lower tumor expression in KIRC and higher tumor expression in LUAD, LIHC, LUSC, BLCA and STAD. The LUAD box plot shows higher UQCRH RNA expression in tumor versus normal tissue (log2 FC = +0.796, t-test p < 0.001).
This table shows molecular features associated with UQCRH in patient tissues and cancer cell lines. In patient samples, UQCRH shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCRH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BONE.
